Cipher Pharmaceuticals (TSE:CPH) Stock Price Crosses Below Fifty Day Moving Average - Time to Sell?

Key Points

• Cipher Pharmaceuticals shares fell below their 50-day moving average, trading as low as C$13.33 and last changing hands at C$13.39, down 1.9%. The stock’s 200-day moving average is higher at C$16.03.
• The company reported quarterly revenue of C$17.14 million and EPS of C$0.21, alongside a 58.81% net margin and 22.74% return on equity. Analysts expect full-year EPS of approximately C$1.29.
• Director Craig Mull purchased 20,000 shares for about C$283,200, increasing his ownership by 2.02%; insiders collectively own 42% of Cipher’s stock.

Shares of Cipher Pharmaceuticals Inc. (TSE:CPH - Get Free Report) NASDAQ: CPHR crossed below its fifty day moving average during trading on Friday. The stock has a fifty day moving average of C$13.99 and traded as low as C$13.33. Cipher Pharmaceuticals shares last traded at C$13.39, with a volume of 3,809 shares traded.

Cipher Pharmaceuticals Stock Down 1.9%

The firm has a market cap of C$340.31 million, a price-to-earnings ratio of 11.96 and a beta of 1.26. The firm has a 50 day moving average of C$13.99 and a 200 day moving average of C$16.03. The company has a quick ratio of 2.67, a current ratio of 1.59 and a debt-to-equity ratio of 0.27.

Cipher Pharmaceuticals (TSE:CPH - Get Free Report) NASDAQ: CPHR last issued its earnings results on Tuesday, August 11th. The company reported C$0.21 earnings per share (EPS) for the quarter. Cipher Pharmaceuticals had a net margin of 58.81% and a return on equity of 22.74%. The business had revenue of C$17.14 million for the quarter. As a group, sell-side analysts predict that Cipher Pharmaceuticals Inc. will post 1.29 earnings per share for the current year.

Insider Buying and Selling at Cipher Pharmaceuticals

In other news, Director Craig Mull bought 20,000 shares of the business's stock in a transaction that occurred on Friday, September 18th. The shares were bought at an average cost of C$14.16 per share, for a total transaction of C$283,200.00. Following the acquisition, the director directly owned 1,009,953 shares in the company, valued at approximately C$14,300,934.48. This trade represents a 2.02% increase in their ownership of the stock. 42.00% of the stock is owned by insiders.

Cipher Pharmaceuticals Company Profile

Cipher Pharmaceuticals TSX: CPH OTCQX: CPHRF is a specialty pharmaceutical company with a robust and diversified portfolio of commercial and early to late-stage products, mainly in dermatology. Cipher acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and currently markets those products in Canada, the U.S., and South America.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.